{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:46:29Z","timestamp":1793166389729,"version":"4.5.0"},"reference-count":44,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018944","name":"Grupo Ferrer Internacional, S.A","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Pulmonary hypertension (PH) associated with lung disease (Group 3 PH) is a serious complication that negatively impacts patient outcomes. This study aimed to assess the epidemiology and disease burden of Group 3 PH in the UK, focusing on interstitial lung disease (ILD-PH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Electronic medical records from the Clinical Practice Research Datalink Aurum, linked to Hospital Episode Statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>6690 incident cases of Group 3 PH, including 1561 ILD-PH cases, were identified from a sample of approximately 33 million individuals between January 2017 and December 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Primary outcomes included prevalence and incidence of Group 3 PH and ILD-PH. Secondary outcomes included patient characteristics, overall survival, hospitalisations, outpatient visits and healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over the 3-year period, prevalence and annual incidence were 139\/million (95%\u2009CI 134 to 142) and 73\/million\/year (95%\u2009CI 70 to 76) for Group 3\u2009PH and 36\/million (95%\u2009CI 33 to 37.3) and 17\/million\/year (95%\u2009CI 16 to 19) for ILD-PH. Median overall survival was 19.3 (95% CI 17.77 to 20.8) for Group 3\u2009PH and 15.1 months (95%\u2009CI 12.66 to 18.2) for ILD-PH. Following a PH diagnosis, all-cause inpatient visits increased by 33.6% from baseline. The all-cause annual hospitalisation rate was 1.63 (95% CI 1.6 to 1.65) for Group 3\u2009PH and 1.36 (95% CI 1.31 to 1.4) for ILD-PH, with about half linked to PH diagnosis. Pulmonologists were the most consulted specialists, averaging 1.78 (95% CI 1.76 to 1.81) and 2.31 (95% CI 2.25 to 2.37) visits per patient per year for Group 3\u2009PH and ILD-PH, respectively. Annual per-patient costs were \u00a37761 (95% CI 7759 to 7762) for Group 3\u2009PH and \u00a37170 (95% CI 7167.17 to 7173.69) for ILD-PH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Incidence and prevalence of Group 3 PH in the UK are consistent with other European countries. Patients had poor survival, with PH associated with half of hospital admissions, highlighting the negative impact of PH in chronic lung disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-108228","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:40:41Z","timestamp":1772203241000},"page":"e108228","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence and prevalence of pulmonary hypertension in chronic lung disease: insights from a retrospective cohort study using a UK nationwide health database"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-6502","authenticated-orcid":false,"given":"David G","family":"Kiely","sequence":"first","affiliation":[{"name":"Sheffield Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"},{"name":"Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S John","family":"Wort","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Hypertension, Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5318-3811","authenticated-orcid":false,"given":"Diego","family":"Funes","sequence":"additional","affiliation":[{"name":"Ferrer International SA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4545-5300","authenticated-orcid":false,"given":"Miriam","family":"Fernandez Delgado","sequence":"additional","affiliation":[{"name":"Ferrer International SA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9372-3687","authenticated-orcid":false,"given":"Nicoleta","family":"Petrica","sequence":"additional","affiliation":[{"name":"Alira Health, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Proenca","sequence":"additional","affiliation":[{"name":"Alira Health AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-3656","authenticated-orcid":false,"given":"Gabriela","family":"Bacchini Jeanneret","sequence":"additional","affiliation":[{"name":"Ferrer International SA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026022706403847000_16.2.e108228.1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.15.2357"},{"key":"2026022706403847000_16.2.e108228.2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"2026022706403847000_16.2.e108228.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00078411"},{"key":"2026022706403847000_16.2.e108228.4","article-title":"Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease","volume":"14","author":"Lawrence","year":"2024","journal-title":"Life (Basel)"},{"key":"2026022706403847000_16.2.e108228.5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026022706403847000_16.2.e108228.6","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0220-2021"},{"key":"2026022706403847000_16.2.e108228.7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02414-2022","article-title":"Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study","volume":"61","author":"Waxman","year":"2023","journal-title":"Eur Respir J"},{"key":"2026022706403847000_16.2.e108228.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-017-0399-1","article-title":"Healthcare burden of pulmonary hypertension owing to lung disease and\/or hypoxia","volume":"17","author":"Heresi","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2026022706403847000_16.2.e108228.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-024-03141-3","article-title":"Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis","volume":"24","author":"Heresi","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026022706403847000_16.2.e108228.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-023-02698-9","article-title":"Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis","volume":"23","author":"Weiss","year":"2023","journal-title":"BMC Pulm Med"},{"key":"2026022706403847000_16.2.e108228.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-002116","article-title":"Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study","volume":"11","author":"Weatherald","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026022706403847000_16.2.e108228.12","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2026022706403847000_16.2.e108228.13","unstructured":"Characterization of the epidemiology, treatment patterns and burden of pulmonary hypertension group 1 and 3 in the UK: a real-word evidence study. 2023. Available: https:\/\/www.cprd.com\/approved-studies\/characterization-epidemiology-treatment-patterns-and-burden-pulmonary-hypertension"},{"key":"2026022706403847000_16.2.e108228.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2026022706403847000_16.2.e108228.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2011.01277.x"},{"key":"2026022706403847000_16.2.e108228.16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.seizure.2023.01.003","article-title":"The incidence and prevalence of epilepsy in the United Kingdom 2013-2018: A retrospective cohort study of UK primary care data","volume":"105","author":"Wigglesworth","year":"2023","journal-title":"Seizure"},{"key":"2026022706403847000_16.2.e108228.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjspcare-2018-001514","article-title":"Do GPs accurately record date of death? A UK observational analysis","volume":"10","author":"Harshfield","year":"2020","journal-title":"BMJ Support Palliat Care"},{"key":"2026022706403847000_16.2.e108228.18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4747"},{"key":"2026022706403847000_16.2.e108228.19","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1080\/03007995.2023.2271862","article-title":"Estimating the direct healthcare utilization and cost of musculoskeletal pain among people with comorbidity: a retrospective electronic health record study","volume":"39","author":"Png","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"2026022706403847000_16.2.e108228.20","unstructured":"Care and Outcomes Research Centre . Unit costs 2022-2027. 2025. Available: https:\/\/research.kent.ac.uk\/corec\/unit-costs-2022-2027\/"},{"key":"2026022706403847000_16.2.e108228.21","unstructured":"Previous releases of R for windows. 2025. Available: https:\/\/cran.r-project.org\/bin\/windows\/base\/old\/"},{"key":"2026022706403847000_16.2.e108228.22","unstructured":"TimDavenport . Release notes for semi-annual enterprise channel releases - office release notes. 2025. Available: https:\/\/learn.microsoft.com\/en-us\/officeupdates\/semi-annual-enterprise-channel"},{"key":"2026022706403847000_16.2.e108228.23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/MCP.0000000000000790","article-title":"Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment","volume":"27","author":"Behr","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"2026022706403847000_16.2.e108228.24","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2147\/COPD.S359873","article-title":"The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis","volume":"Volume 17","author":"Zhang","year":"2022","journal-title":"COPD"},{"key":"2026022706403847000_16.2.e108228.25","doi-asserted-by":"crossref","first-page":"00039","DOI":"10.1183\/23120541.00039-2024","article-title":"Unmet need in pulmonary hypertension-associated interstitial lung disease (PH-ILD): a clinician survey of real-world management of PH-ILD in Europe","volume":"10","author":"Montani","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026022706403847000_16.2.e108228.26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/15412555.2017.1336209","article-title":"Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population","volume":"14","author":"Medrek","year":"2017","journal-title":"COPD"},{"key":"2026022706403847000_16.2.e108228.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001291","article-title":"Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review","volume":"10","author":"Shah Gupta","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2026022706403847000_16.2.e108228.28","doi-asserted-by":"crossref","first-page":"751181","DOI":"10.3389\/fmed.2021.751181","article-title":"Variability in Global Prevalence of Interstitial Lung Disease","volume":"8","author":"Kaul","year":"2021","journal-title":"Front Med"},{"key":"2026022706403847000_16.2.e108228.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0827-5","article-title":"The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients","volume":"19","author":"Armstrong","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026022706403847000_16.2.e108228.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006604","article-title":"Exposure to sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the QResearch primary care database","volume":"4","author":"Fairhurst","year":"2014","journal-title":"BMJ Open"},{"key":"2026022706403847000_16.2.e108228.31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.14378","article-title":"Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study","volume":"28","author":"Dawes","year":"2023","journal-title":"Respirology"},{"key":"2026022706403847000_16.2.e108228.32","unstructured":"NHS England Digital . National pulmonary hypertension audit. 2025. Available: https:\/\/digital.nhs.uk\/data-and-information\/clinical-audits-and-registries\/national-pulmonary-hypertension-audit"},{"key":"2026022706403847000_16.2.e108228.33","unstructured":"Power BI report. 2025. Available: https:\/\/app.powerbi.com\/view?r=eyJrIjoiMmMzYzlmNGMtZDBlMS00MzAyLTg0N2EtOWY4NzliMGQ1NTdlIiwidCI6IjM3YzM1NGIyLTg1YjAtNDdmNS1iMjIyLTA3YjQ4ZDc3NGVlMyJ9"},{"key":"2026022706403847000_16.2.e108228.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2017.02.016"},{"key":"2026022706403847000_16.2.e108228.35","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079512"},{"key":"2026022706403847000_16.2.e108228.36","unstructured":"ERS Respiratory Channel . Incidence and survival of interstitial lung diseases in the UK in 2000-2022: real-world data from the OPCRD primary care database, Vienna. 2024. Available: https:\/\/channel.ersnet.org\/\\\\channel.ersnet.org\/container-detail.php?id=113470"},{"key":"2026022706403847000_16.2.e108228.37","doi-asserted-by":"crossref","DOI":"10.3390\/cells12192394","article-title":"Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics","volume":"12","author":"Haynes","year":"2023","journal-title":"Cells"},{"key":"2026022706403847000_16.2.e108228.38","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00058-2022","article-title":"Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001-2017","volume":"8","author":"Salciccioli","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026022706403847000_16.2.e108228.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-024-03235-y","article-title":"Mortality from pulmonary hypertension in Europe 2001-2019","volume":"24","author":"Hartley","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026022706403847000_16.2.e108228.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m693","article-title":"Health equity in England: the Marmot review 10 years on","volume":"368","author":"Marmot","year":"2020","journal-title":"BMJ"},{"key":"2026022706403847000_16.2.e108228.41","doi-asserted-by":"crossref","unstructured":"Arslan A , Smith J , Qureshi MR , et al . Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future. Front Med 2024;10. doi:10.3389\/fmed.2023.1306032","DOI":"10.3389\/fmed.2023.1306032"},{"key":"2026022706403847000_16.2.e108228.42","first-page":"S2","article-title":"Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment","volume":"31","author":"Nathan","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"2026022706403847000_16.2.e108228.43","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.121.319970","article-title":"Group 3 Pulmonary Hypertension: From Bench to Bedside","volume":"130","author":"Singh","year":"2022","journal-title":"Circ Res"},{"key":"2026022706403847000_16.2.e108228.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-022-01922-2","article-title":"A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies","volume":"22","author":"Wong","year":"2022","journal-title":"BMC Pulm Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-108228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:40:46Z","timestamp":1772203246000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-108228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-108228"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-108228","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}